MRK today
$147.18-$0.87 (-0.59%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourBullish
15 minLeaning Bearish
5 minBullish
Daily trend turns down below $126.22
Key levels
Resistance$153.37
Support$142.80
Support$131.47
Latest news & SEC filings
GuidanceMerck KGaA lifts 2026 full-year guidance after strong Q3 results
ProductMerck KGaA receives FDA approval for tumor drug licensed from Abbisko
ProductUS regulator clears Merck's pimicotinib, sold as PIMJETMI, for tenosynovial giant cell tumor
All MRK news →About Merck
Merck is a worldwide health care company that runs two businesses: Pharmaceutical and Animal Health. The Pharmaceutical unit develops prescription drugs, biologic treatments, and vaccines for conditions such as cancer, infectious diseases, diabetes, and heart and lung disorders, selling to drug distributors, medical centers, public health bodies, and managed care organizations. The Animal Health unit makes medicines, vaccines, and tracking tools for livestock and pets, reaching veterinarians, animal producers, and households across many regions.
Based on the company's 10-K filed Feb 24, 2026.
NYSE · Healthcare
Merck & Co., Inc. (MRK)
What Is the Price Target for MRK?
SEPT Low Target
$140.00
SEPT Mid Target
$170.50
SEPT High Target
$180.00
Analyst Consensus
$170.50
Is MRK a Buy or Sell Right Now?
Thesis
- •Revenue growing 1.3% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MRK.
Start Free Trial →Is MRK Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$146.33
10
Moat Score
NONE
4/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with MRK?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
BUYING
9 buys / 11 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MRK Growth Story
Revenue YoY
1.3%
3yr Revenue CAGR
3.1%
EPS Growth YoY
8.01%
FCF Growth YoY
-31.7%
Revenue Trend
SLOWING
Dark Pool Trades for MRK
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MRK, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:57:47 | $147.18 | 2,093 | $$308K | BUY |
| 21:28:26 | $147.18 | 38,475 | $$5.7M | BUY |
| 21:21:59 | $147.18 | 2,216 | $$326K | BUY |
| 21:16:20 | $147.18 | 1,310 | $$193K | BUY |
| 21:03:26 | $147.18 | 180,896 | $$26.6M | SELL |
5 dark pool trades shown · $$33.1M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for MRK
PREVIEWSEPT Investing provides real-time options flow tracking for MRK, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $175 | Dec 18 | 37 | $$192 | 12 | SWEEP |
| CALL | $175 | Dec 18 | 37 | $$16 | 1 | SWEEP |
| CALL | $175 | Dec 18 | 37 | $$80 | 5 | SWEEP |
| CALL | $175 | Dec 18 | 37 | $$64 | 4 | SWEEP |
| CALL | $175 | Dec 18 | 37 | $$160 | 10 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Merck & Co., Inc. (MRK) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MRK — frequently asked questions
What is MRK stock price today?
Merck & Co., Inc. (MRK) is at $147.18, down 0.59% (-$0.87) at the Nov 11, 2026 close.
Why is MRK stock moving today?
Latest MRK news — Nov 12, 2026: Merck KGaA lifts 2026 full-year guidance after strong Q3 results · Nov 11, 2026: Merck KGaA receives FDA approval for tumor drug licensed from Abbisko
Why did MRK stock move on Oct 26, 2026?
Merck & Co. shares fell 3.63% to close at $140.59, trading between $139.93 and $146.61 on volume of about 10.1 million shares.
What is the MRK price target?
The average analyst price target for MRK is $170.50, ranging from $140 to $180, based on 18 analysts. Latest: Cantor Fitzgerald maintains on Nov 2, 2026.
What do analysts rate MRK?
Analyst ratings for MRK: 2 Buy, 37 Hold, 1 Sell — consensus Hold.
Did MRK beat earnings?
MRK last reported on Oct 29, 2026: EPS $2.49 vs $2.09 expected — a beat of 19.1%.
What is MRK's P/E ratio?
MRK trades at a P/E of 151.7 vs a Healthcare average of 17.7.
Does MRK pay a dividend?
Yes. MRK's dividend yield is 3.10%.
What are MRK support and resistance levels?
Support: $142.80, $131.47, $126.22. Resistance: $153.37.
What are insiders doing with MRK?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on MRK?
Nov 12, 2026: Merck KGaA lifts 2026 full-year guidance after strong Q3 results · Nov 11, 2026: Merck KGaA receives FDA approval for tumor drug licensed from Abbisko · Nov 10, 2026: US regulator clears Merck's pimicotinib, sold as PIMJETMI, for tenosynovial giant cell tumor